Innocan Pharma Corp. Stock
€0.21
Your prediction
Financial data and news for Innocan Pharma Corp.
sharewise wants to provide you with the best news and tools for Innocan Pharma Corp., so we directly link to the best financial data sources.
Financials
News
Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory Board
Herzliya, Israel and Calgary, Alberta (September 15, 2023) Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneering pharmaceutical technology
Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test
- Innocan hair care cream efficacy trial observes enhanced hair growth in male and female participants in a 14day period.
- 91 % of participants reported stronger hair and
Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD Injection
Herzliya, Israel and Calgary, Alberta – August 29, 2023 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) is pleased to announce the results of a
Innocan Pharma Reports Q2 2023 Results Including US$2.706M Increase in Revenues Compared to Q2, 2022
- US$3.121M Revenues for Q2, 2023 compared to US$415,000 for Q2 2022, representing an increase of 652%
- US$2.656M Gross Profit for Q2, 2023 compared to USD 214,000 for
Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief Treatment
Herzliya, Israel and Calgary, Alberta (August 15, 2023) Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company
Innocan Pharma Announces Closing of Private Placement
Herzliya, Israel and Calgary, Alberta – (August 4, 2023) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”) is pleased to announce that it has
Innocan Pharma Announces Private Placement of Units at a 9% Prime Above Share Price
Herzliya, Israel and Calgary, Alberta, July 25, 2023 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”) is pleased to announce that it intends to
Innocan Pharma Unveils Groundbreaking Veterinary Breakthroughs at EAVPT 2023 Congress
Herzliya, Israel and Calgary, Alberta - June 22, 2023 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF), a leading innovator in pharmaceutical solutions for Human & Animal
InnoCan Pharma Submits New Patent Applications for Advanced Pain Relief Technology
The Patent Application is in line with Innocan’s Strategy to Expand the Scope of its Combined Magnesium and Cannabis Topical Solution
June 12, 2023 - InnoCan Pharma Corporation (CSE:INNO)
Innocan Pharma Reports Q1 2023 Results including US$1.3M Increase in Revenues Compared to Q1 2022
- USD 1.4M Gross Profit, compared to USD 78K last year
- USD 4.1M Cash Balance along the entire corporate structure
- USD 1.3M Increase in Revenues Compared to Q1
Innocan Pharma Reports Success in a Pre-Clinical Trial of a Liposomal-CBD Injection on a Paralyzed Goat
Herzliya, Israel and Calgary, Alberta (May 8, 2023) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a leading pharmaceutical and biotech
Innocan Reports Novel Cannabinoid Delivery Platform Patent Application
The application pertains to the development of a novel platform for loading Cannabinoids on Exosomes.
Herzliya, Israel and Calgary, Alberta (April 3, 2023) – Innocan Pharma Corporation
